|
WO2010085246A1
|
|
2,4-diamino-1,3,5-triazine and 4, 6-diamino-pyrimidine derivatives and their use as aggrecanase inhibitors
|
|
EP2054377A1
|
|
Chemical compounds
|
|
EP2099768A2
|
|
Agonists of the sphingosine-1-phosphate receptor
|
|
CN101522625A
|
|
Chemical compounds
|
|
WO2008016674A1
|
|
Agonists of the sphingosine- 1- phosphate receptor (slp)
|
|
TW200823182A
|
|
Chemical compounds
|
|
EP2441757A1
|
|
Aurora kinase inhibitors from an encoded small molecule library
|
|
AU2007202669A1
|
|
Modulators of amyloid aggregation
|
|
US2007254303A1
|
|
Methods for assessing the efficacy of treatment with a glucocorticoid
|
|
US2007254843A1
|
|
Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors
|
|
EP2368868A1
|
|
Methods for identifying compounds of interest using encoded libraries
|
|
US2007161570A1
|
|
Methionine aminopeptidase-2 inhibitors and methods of use thereof
|
|
NZ564545A
|
|
Methods for synthesis of encoded libraries
|
|
US2006223866A1
|
|
Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
|
|
US2007185032A1
|
|
Pharmaceutical formulations for sustained drug delivery
|
|
US2006198815A1
|
|
Pharmaceutical formulations for sustained release
|
|
US2006177417A1
|
|
Pharmaceutical formulations for sustained drug delivery
|
|
US2006293217A1
|
|
Pharmaceutical formulations for sustained release
|
|
US2007185033A1
|
|
Pharmaceutical formulations for sustained drug delivery
|
|
CN101018761A
|
|
Methods and compositions for modulating sphingosine-1-phosphate(S1P) receptor activity
|
